Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7469.09 | 1.0362 | 1.0362 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7469.09 | 1.0783 | 1.0774 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7469.09 | 1.0134 | 1.0135 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7469.09 | 1.0049 | 1.0050 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7469.09 | 0.9905 | 0.9904 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7469.09 | 0.8757 | 0.8708 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7469.09 | 0.0089 | -0.8139 | 1.9867 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7469.09 | 0.0095 | -0.8077 | 1.9867 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7470.091 | 0.9661 | 0.9307 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7470.091 | 0.9344 | 0.8659 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7470.091 | 0.9815 | 0.9620 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7470.091 | 1.0008 | 1.0017 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7470.091 | 1.0747 | 1.1531 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7470.091 | 0.9135 | 0.8231 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7470.091 | 0.6677 | 0.3229 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7470.091 | 0.0111 | -0.9800 | 0.9773 | |
| HCC70 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7470.091 | 0.0046 | -0.9918 | 0.9773 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7471.092 | 0.9434 | 0.7196 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7471.092 | 0.9346 | 0.6784 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7471.092 | 0.9537 | 0.7687 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7471.092 | 1.0412 | 1.2205 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7471.092 | 1.0645 | 1.3517 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7471.092 | 0.7007 | -0.2040 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7471.092 | 0.2681 | -0.9339 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7471.092 | 0.0039 | -1.0000 | 0.3860 |